CAJ | 학술논문

目的：探讨阿奇霉素联合红霉素治疗支原体肺炎的临床疗效及安全性，为提高临床治疗效果提供参考依据。方法选取2013年1月－2014年1月医院收治的120例支原体肺炎患儿为研究对象，随机将其分为对照组和观察组，每组各60例，对照组患儿给予红霉素治疗，观察组患儿给予阿奇霉素联合红霉素治疗，对两组临床疗效、症状改善及不良反应进行观察和比较。结果观察组显效率95．0％，对照组80．0％，观察组明显高于对照组，两组比较差异有统计学意义（P＜0．05），观察组退热时间为（3．8±1．5）d、止咳时间（3．2±0．5）d、肺部啰音消失时间（5．6±2．3）d、不良反应发生率11．7％，对照组分别为（4．5±1．5）d、（4．5±1．0）d、（7．8±2．5）d、40．0％，观察组时间均明显缩短，不良反应发生率显著降低，两组比较差异均有统计学意义（P＜0．05）。结论阿奇霉素联合红霉素治疗支原体肺炎感染的疗效显著，明显改善患者预后质量，不良反应少，安全性较高，值得临床推广应用。
목적：탐토아기매소연합홍매소치료지원체폐염적림상료효급안전성，위제고림상치료효과제공삼고의거。방법선취2013년1월－2014년1월의원수치적120례지원체폐염환인위연구대상，수궤장기분위대조조화관찰조，매조각60례，대조조환인급여홍매소치료，관찰조환인급여아기매소연합홍매소치료，대량조림상료효、증상개선급불량반응진행관찰화비교。결과관찰조현효솔95．0％，대조조80．0％，관찰조명현고우대조조，량조비교차이유통계학의의（P＜0．05），관찰조퇴열시간위（3．8±1．5）d、지해시간（3．2±0．5）d、폐부라음소실시간（5．6±2．3）d、불량반응발생솔11．7％，대조조분별위（4．5±1．5）d、（4．5±1．0）d、（7．8±2．5）d、40．0％，관찰조시간균명현축단，불량반응발생솔현저강저，량조비교차이균유통계학의의（P＜0．05）。결론아기매소연합홍매소치료지원체폐염감염적료효현저，명현개선환자예후질량，불량반응소，안전성교고，치득림상추엄응용。
OBJECTIVE To explore the clinical efficacy and safety of azithromycin combined with erythromycin in treatment of the children with Mycoplasma pneumonia so as to improve the clinical therapeutic effect .METHODS A total of 120 children with M .pneumoniawho were treated from Jan 2013 to Jan 2014 were recruited as the study objects and randomly divided into the observation group and the control group ,with 60 cases in each .The control group was treated with erythromycin ,while the observation group was given azithromycin combined with erythro‐mycin;the clinical efficacy ,improvement of symptoms ,and adverse reactions were observed and compared be‐tween the two groups .RESULTS The effective rate of the observation group was 95 .0% ,significantly higher than 80 .0% of the control group (P<0 .05) .The time of fever of the observation group was (3 .8 ± 1 .5) days ,signifi‐cantly shorter than (4 .5 ± 1 .5) days of the control group;the time of relieving cough of the observation group was (3 .2 ± 0 .5) days ,significantly shorter than (4 .5 ± 1 .0) days of the control group;the time of disappearance of pulmonary rales of the observation group was (5 .6 ± 2 .3) days ,significantly shorter than (7 .8 ± 2 .5) days of the control group;the incidence of adverse reactions of the observation group was 11 .7% ,significantly lower than 40 .0% of the control group (P<0 .05) .CONCLUSION Azithromycin combined with erythromycin can achieve re‐markable efficacy in treatment of M .pneumonia ,significantly improve the prognosis of the patients ,with the inci‐dence of adverse reactions low ,the safety high ,and it is worthy to be promoted in the hospital .